首页> 外文期刊>Indian heart journal >Prospective evaluation of outcome of Indian patients who meet MADIT II (Multicenter Automatic Defibrillator Implantation Trial) criteria for implantable cardioverter defibrillator implantation: is it appropriate for Indian patients?
【24h】

Prospective evaluation of outcome of Indian patients who meet MADIT II (Multicenter Automatic Defibrillator Implantation Trial) criteria for implantable cardioverter defibrillator implantation: is it appropriate for Indian patients?

机译:符合MADIT II(多中心自动除颤器植入试验)植入心脏除颤器植入标准的印度患者结果的前瞻性评价:印度患者是否适合?

获取原文
       

摘要

Background The MADIT II investigators had concluded that prophylactic use of an ICD improved survival in patients with prior myocardial infarction reduced left ventricular ejection fraction. Whether MADIT II criteria for ICD implantation are appropriate for Indian patients also is unclear and not studied. Methods A total of 144 patients, Mean age 56.23?±?10.9 years who met MADIT II criteria were prospectively followed for 20.78?+?5.9 months. Results During the follow-up period, 26 (18.1%) patients died. 18 were sudden cardiac deaths and 8 were non SCD deaths. Total mortality did not correlate with Age, NYHA class, NSVT on Holter, PVC 10/hours, QRS width, or use of statins. Multivariate logistic regression model identified the following variables associated with increase all-cause mortality: No use of beta blocker (odd ratio:13.068, p?=?0.021), No past revascularization (odd ratio:11.613,p?=?0.007) and Increase serum creatinine level (odd ratio: 4.066, p?=?0.035). The mortality rate in the present series was comparable with that in the MADIT II conventional therapy group though patient in present study are younger, less diabetic, hypertensive, smokers and better treated with beta-blockers, ACE/ARB and statin. Conclusion Indian patients with prior MI (more than one month back) and left ventricular ejection fraction of 30% or less had a cardiac mortality similar to western population who are not treated with prophylactic ICD. Patients of Indian origin should derive a similar benefit with prophylactic implantation of ICD as per MADIT II criteria as would a western population.
机译:背景技术MADIT II调查人员得出结论,预防ICD的使用改善了先前心肌梗死的患者存活率降低了左心室喷射部分。 ICAT II植入型素质是否适合印度患者也不清楚,并未研究。方法总共144名患者,平均年龄为56.23岁?±10.9岁,达到Madit II标准,预期为20.78?+ 5.9个月。结果在后续期间,26例(18.1%)患者死亡。 18突发的心脏死亡和8例是非SCD死亡。总死亡率与年龄,NYHA类,NSVT在HOLTER,PVC> 10 /小时,QRS宽度或使用他汀类药物上的年龄没有相关。多变量逻辑回归模型确定了随着增加的所有原因死亡率相关的以下变量:不使用β受体阻滞剂(奇数比例:13.068,p?= 0.021),没有过去的血运重建(奇数比例:11.613,p?= 0.007)和增加血清肌酐水平(奇数比例:4.066,p?= 0.035)。本系列中的死亡率与MADIT II常规治疗组的死亡率相当,虽然目前研究的患者更年轻,糖尿病患者较少,较少的糖尿病,高血压,吸烟者,并且用β-封锁剂,ACE / ARB和他汀类药物更好地治疗。结论印度患者(超过一个月返回)和左心室喷射分数30%以下的心脏死亡率类似于未受预防ICD治疗的西方人群。印度患者应根据西部人群的麦迪特II标准导出ICD的预防性植入类似的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号